Search Result

Results for "

Integrase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HIV Integrase (41) Dynamin (1) Endogenous Metabolite (1) GLUT (1) HIV (36) Isotope-Labeled Compounds (9) Tyrosinase (1)
By Research Areas:	Cancer (3) Infection (48) Inflammation/Immunology (3) Metabolic Disease (1)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: HIV Integrase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107485

HIV-1 integrase inhibitor 8

HIV Integrase Infection

HIV-1 integrase inhibitor 8 is a HIV-1 integrase inhibitor, compound 8 .

*HIV-1 integrase* inhibitor 8**	HIV Integrase	Infection
HIV-1 integrase inhibitor 8 is a HIV-1 integrase inhibitor, compound 8 .

HY-147653

Integrase-LEDGF/p75 allosteric inhibitor 1	HIV Integrase	Infection
Integrase-LEDGF/p75 allosteric inhibitor 1 (Compound 31h) is an orally active integrase-LEDGF/p75 (IN-LEDGF/p75) allosteric inhibitor. Integrase-LEDGF/p75 allosteric inhibitor 1 inhibits HIV-1 DNA integration and shows antiviral activity with an EC₅₀ of 3.9 nM against HIV-1 recombinant molecular clone NL432 .

HY-130760

HIV-1 integrase inhibitor 7

HIV Integrase Infection

HIV-1 integrase inhibitor 7 is a potent HIV-1 integrase inhibitor, with an IC₅₀ of 33.3 nM .

*HIV-1 integrase* inhibitor 7**	HIV Integrase	Infection
HIV-1 integrase inhibitor 7 is a potent HIV-1 integrase inhibitor, with an IC₅₀ of 33.3 nM .

HY-150079

*HIV-1 integrase* inhibitor 10**	HIV Integrase	Infection
HIV-1 integrase inhibitor 10 is an orally active HIV-1 allosteric integrase inhibitor (ALLINI). HIV-1 integrase inhibitor 10 can inhibit viral outgrowth of the NLRepRluc virus in MT-2 cells with EC₅₀ values of 3-5 nM. HIV-1 integrase inhibitor 10 can be used for the research of Human immunodeficiency virus-1 (HIV-1) .

HY-108817

HIV-1 integrase inhibitor 3

HIV Integrase HIV Infection

HIV-1 integrase inhibitor 3 is a HIV-1 integrase strand transfer (INST) inhibitor with an IC₅₀ of 2.7 nM.
HY-108820

HIV-1 integrase inhibitor 4

HIV Integrase HIV Infection

HIV-1 integrase inhibitor 4 is a HIV-1 integrase strand transfer (INST) inhibitor with an IC₅₀ of 3.7 nM.

*HIV-1 integrase* inhibitor 3**	HIV Integrase HIV	Infection
HIV-1 integrase inhibitor 3 is a *HIV-1 integrase* strand transfer (INST) inhibitor with an IC₅₀** of 2.7 nM.

*HIV-1 integrase* inhibitor 4**	HIV Integrase HIV	Infection
HIV-1 integrase inhibitor 4 is a *HIV-1 integrase* strand transfer (INST) inhibitor with an IC₅₀** of 3.7 nM.

HY-132572

*HIV-1 integrase* inhibitor 9**	HIV	Infection
HIV-1 integrase inhibitor 9 (compound 8a) is a potent HIV-1 RNase H inhibitor with an IC₅₀ of 12.3 μM. HIV-1 integrase inhibitor 9 shows an antiviral activity .

HY-13025

*HIV-1 integrase* inhibitor** 1 Publications Verification	HIV HIV Integrase	Infection
HIV-1 integrase inhibitor is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-N7330

Integracin B	HIV Integrase HIV	Infection
Integracin B is a potent dimeric alkyl aromatic inhibitor of HIV-1 integrase discovered from the screening of fungal extracts using an in vitro assay. Integracin B inhibits both coupled and strand transfer activity of HIV-1 integrase .

HY-108818

XZ426

HIV Integrase Infection

XZ426 is a potent integrase strand transfer inhibitor with anti- HIV activity .

XZ426	HIV Integrase	Infection
XZ426 is a potent integrase strand transfer inhibitor with anti- HIV activity .

HY-108935

Lavendustin B	HIV Integrase GLUT Tyrosinase	Cancer
Lavendustin B is an inhibitor of *HIV-1 integrase* interaction with LEDGF/p75 with an IC₅₀ of 94.07 μM. Lavendustin B is an ATP-competitive GLUT1 inhibitor with a K_i of 15 µM. Lavendustin B is also a weak inhibitor of tyrosine kinases** .

HY-12210

(S)-BI-1001	HIV Integrase	Infection
(S)-BI-1001 (Compound 11) is an active S-enantiomer of BI-1001. (S)-BI-1001 exhibits antiviral potency against HIV-1 integrase with an IC₅₀ of 28 nM, an EC₅₀ of 450 nM and a K_d of 4.7 μM .

HY-130000

Pirmitegravir STP0404	HIV Integrase HIV	Infection
Pirmitegravir is a potent and first-in-class inhibitor of allosteric integrase (ALLINI) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC₅₀ in human PBMCs with a >24,000 therapeutic index against HIV-1. Pirmitegravir harbors outstanding anti-virus and safety properties .

HY-123572

Bis-T-23 AG1717	Dynamin HIV Integrase	Infection Metabolic Disease Inflammation/Immunology
Bis-T-23 (AG1717), tyrphostin derivative, is an HIV-I integrase inhibitor. Bis-T-23 can promote actin-dependent dynamin oligomerization. Bis-T-23 can be used for the research of HIV and chronic kidney diseases (CKD) .

HY-153247

GSK3839919A

HIV Integrase Infection Inflammation/Immunology

GSK3839919A is a potent and allosteric HIV-1integrase inhibitor .

GSK3839919A	HIV Integrase	Infection Inflammation/Immunology
GSK3839919A is a potent and allosteric *HIV-1integrase* inhibitor .

HY-13269

BMS-707035 1 Publications Verification	HIV HIV Integrase	Infection Inflammation/Immunology
BMS-707035 is a potent orally active *HIV-1 integrase* strand transfer inhibitor (INSTI). BMS-707035 has enzyme inhibitory with an IC₅₀** value of 3 nM. BMS-707035 also has weak CYP inhibiton and antiviral activity. BMS-707035 can be used for the research of human immunodeficiency virus-1 (HIV-1) .

HY-10353

Raltegravir Maximum Cited Publications 18 Publications Verification MK-0518	HIV Integrase HIV	Infection Cancer
Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.

HY-10353A

Raltegravir potassium Maximum Cited Publications 18 Publications Verification MK 0518 potassium	HIV Integrase HIV	Infection
Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.

HY-10353B

Raltegravir sodium

MK 0518 sodium
HIV Integrase HIV Infection

Raltegravir (MK 0518) sodium is a potent and orally active integrase (IN) inhibitor, used to treat HIV infection.

Raltegravir sodium MK 0518 sodium	HIV Integrase HIV	Infection
Raltegravir (MK 0518) sodium is a potent and orally active integrase (IN) inhibitor, used to treat HIV infection.

HY-153094

BDM-2	HIV HIV Integrase	Infection
BDM-2 is an IN-LEDGF allosteric inhibitor (INLAI) of HIV-1 *integrase* (IN refers to integrase) (IC₅₀=47 nM) with potent anti-Retroviral (ARV) activity. BDM-2 shows IN multimerization activation effect with an AC₅₀ value of 20 nM. BDM-2 blocks the interaction between the catalytic core domain of IN (IN-CCD) and the Integrase binding domain of LEDGF/p75 (IBD), with an IC₅₀ value of 0.15 μM. BDM-2 exhibits highly selective and favorable cytotoxicity .

HY-17605

Bictegravir

5+ Cited Publications

GS-9883
HIV HIV Integrase Infection

Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC₅₀ of 7.5 nM.
HY-18601

(±)-BI-D

5 Publications Verification

HIV HIV Integrase Infection

(±)-BI-D is a potent ALLINI(An allosteric IN inhibitor) that binds integrase at the LEDGF/p75 binding site.
HY-13305

MK-2048

HIV HIV Integrase Infection

MK-2048 is a potent inhibitor of integrase and INR263K with IC50 of 2.6 nM and 1.5 nM, respectively.

Bictegravir 5+ Cited Publications GS-9883	HIV HIV Integrase	Infection
Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC₅₀ of 7.5 nM.

(±)-BI-D 5 Publications Verification	HIV HIV Integrase	Infection
(±)-BI-D is a potent ALLINI(An allosteric IN inhibitor) that binds integrase at the LEDGF/p75 binding site.

MK-2048	HIV HIV Integrase	Infection
MK-2048 is a potent inhibitor of integrase and INR263K with IC50 of 2.6 nM and 1.5 nM, respectively.

HY-10353S

Raltegravir-d4	Isotope-Labeled Compounds HIV Integrase HIV	Infection
Raltegravir-d₄ is deuterium labeled Raltegravir. Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.

HY-10522

LEDGIN6 4 Publications Verification CX05168; CX04328	HIV HIV Integrase	Infection
LEDGIN6 (CX05168) is a quinoline-based protein-protein interaction inhibitor of LEDGF/p75 and HIV integrase .

HY-122229

GS-9822	HIV	Infection
GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits the *LEDGF/p75-integrase* interaction with an IC₅₀ of 0.07 μM. GS-9822 has high in vitro metabolic stability and favorable oral pharmacokinetic profiles with low systemic clearance in rats, dogs, and monkeys .

HY-10353AS

Raltegravir-d3 potassium MK 0518-d₃ potassium	Isotope-Labeled Compounds HIV Integrase HIV	Infection
Raltegravir-d₃ (potassium) is the deuterium labeled Raltegravir potassium. Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection[1][2].

HY-17605A

Bictegravir sodium 5+ Cited Publications GS-9883 sodium	HIV Integrase HIV	Infection
Bictegravir sodium is a potent inhibitor of HIV-1 integrase, with an IC₅₀ of 7.5 nM. Bictegravir sodium exhibits potent and selective anti-HIV activity and low cytotoxicity .

HY-134851

HIV-1 inhibitor-6	HIV	Infection
HIV-1 inhibitor-6 (compound 9), a diheteroarylamide-based compound, is a potent HIV-1 pre-mRNA alternative splicing inhibitor. HIV-1 inhibitor-6 blocks HIV replication. HIV-1 inhibitor-6 is active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC₅₀s of 0.6 μM and 0.9 μM, respectively. HIV-1 inhibitor-6 inhibits HIV strains resistant to agents targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC₅₀s ranging from 0.9 to 1.5 μM .

HY-B1408

Salicylanilide 2 Publications Verification 2-Hydroxybenzanilide	HIV Integrase HIV	Infection
Salicylanilide demonstrates a wide range of biological activities including antiviral potency which can inhibit HIV virus by targeting HIV-1 integrase or reverse transcriptase.

HY-18595

BI 224436 5 Publications Verification	HIV HIV Integrase	Infection
BI 224436 is a novel HIV-1 noncatalytic site integrase inhibitor with EC₅₀ values of less than 15 nM against different HIV-1 laboratory strains.

HY-W751039

Bictegravir-d4 GS-9883-d₄	Isotope-Labeled Compounds	Infection
Bictegravir-d4 is a deuterium of Bictegravir (HY-17605). Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC₅₀ of 7.5 nM .

HY-15592AS

Cabotegravir-d3 sodium GSK-1265744-d₃ sodium; S/GSK1265744-d₃ sodium	Isotope-Labeled Compounds HIV Integrase	Infection
Cabotegravir-d₃ (sodium) is the deuterium labeled Cabotegravir sodium. Cabotegravir sodium is a highly potent HIV integrase inhibitor with an IC50 value of 2.5 nM for HIVADA. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltr

HY-15592S2

Cabotegravir-d3-1 GSK-1265744-d₃-1; S/GSK1265744-d₃-1	Isotope-Labeled Compounds HIV Integrase	Infection
Cabotegravir d3-1 (GSK-1265744-d3-1) is a deuterium substitute of Cabotegravir. Cabotegravir is a potent HIV integrase inhibitor used in AIDS research

HY-N0457A

L-Chicoric Acid 1 Publications Verification (-)-Chicoric acid; trans-Caffeoyltartaric acid	HIV Integrase HIV Endogenous Metabolite	Infection Cancer
L-Chicoric Acid ((-)-Chicoric acid) is a dicaffeoyltartaric acid and a potent, selective and reversible HIV-1 integrase inhibitor with an IC₅₀ of ~100 nM. L-Chicoric Acid inhibits HIV-1 replication in tissue culture .

HY-100083

Dolutegravir intermediate-1	HIV	Others
Dolutegravir intermediate-1 is a synthetic intermediate of Dolutegravir extracted from patent WO 2016125192 A2. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV)-1 infection.

HY-13238

Dolutegravir Maximum Cited Publications 18 Publications Verification S/GSK1349572	HIV Integrase HIV	Infection
Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable *HIV integrase* strand transfer inhibitor with an IC₅₀** of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-13238A

Dolutegravir sodium Maximum Cited Publications 18 Publications Verification S/GSK1349572 sodium	HIV Integrase HIV	Infection
Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable *HIV integrase* strand transfer inhibitor with an IC₅₀** of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-14740

Elvitegravir 5+ Cited Publications GS-9137; JTK-303; D06677	HIV Integrase HIV	Infection
Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1_IIIB, HIV-2_EHO and HIV-2_ROD with IC₅₀ of 0.7 nM, 2.8 nM and 1.4 nM, respectively.

HY-13238S1

Dolutegravir-d3 S/GSK1349572-d₃	Isotope-Labeled Compounds HIV Integrase HIV	Infection
Dolutegravir-d₃ is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM)[1][2].

HY-13238S2

Dolutegravir-d5 S/GSK1349572-d₅	Isotope-Labeled Compounds HIV Integrase HIV	Infection
Dolutegravir-d₅ is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM)[1][2].

HY-17605S

Bictegravir-15N,d2	Isotope-Labeled Compounds	Infection
Bictegravir- ¹⁵N,d₂ (GS-9883- ¹⁵N,d₂) is the ¹⁵N and deuterium labeled Bictegravir (HY-17605) . Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC₅₀ of 7.5 nM .

HY-18666

D77	HIV	Infection
D77 is anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. D77 inhibits HIV-1(IIIB) replication by EC50 value of 23.8 μg/ml in MT-4 cell (5.03 μg/ml for C8166 cells).

HY-14740S

Elvitegravir-d8 GS-9137-d₈; JTK-303-d₈; D06677-d₈	Isotope-Labeled Compounds HIV Integrase HIV	Infection
Elvitegravir-d₈ is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.

HY-163177

HIV-1 inhibitor-63	HIV	Infection
HIV-1 inhibitor-63 (compound S17) is a potent HIV-1 inhibitor. HIV-1 inhibitor-63 inhibits integrase-Ku70 complex formation with an IC₅₀ value of 12 µM. HIV-1 inhibitor-63 inhibits HIV-1 post-integration DNA repair .

HY-150080

GSK3739936 BMS-986180	HIV HIV Integrase	Infection
GSK3739936 (BMS-986180) is a potent HIV-1 allosteric integrase inhibitor with an IC₅₀ value of 11.1 nM and an EC₅₀ value of 1.7 nM. GSK3739936 is also a weak CYP inhibitor (IC₅₀>24.3 μM). GSK3739936 shows favorable pharmacokinetic property in preclinical species with rapid absorption, low to moderate clearance and excellent oral bioavailability .

HY-N11288

Methyl salvionolate A	HIV	Infection
Methyl salvionolate A is a potent inhibitor of HIV-1. Methyl salvionolate A inhibits P24 antigen in HIV-1 infected MT-4 cell with an EC₅₀ of 1.62 μg/ml. Methyl salvionolate A also inhibits HIV-1 reverse transcriptase, protease and integrase with IC₅₀s of 50.58, 10.73 and 7.58 μg/ml, respectively .

HY-15592

Cabotegravir 5 Publications Verification GSK-1265744; S/GSK1265744	HIV HIV Integrase	Infection
Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC₅₀ values of 2.5 nM, 0.41 μM and 0.81 μM for HIV_ADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS .

HY-N6711

Equisetin	HIV Integrase	Infection
Equisetin is an N-methylserine-derived acyl tetramic acid isolated from a terrestrial fungus Fusarium equiseti NRRL 5537 . Equisetin is a tetramate-containing natural product with antibiotic and cytotoxic activity . Equisetin inhibits the growth of Gram-positive bacteria and HIV-1 integrase activity but shows no activity against Gram-negative bacteria . Equisetin is a Quorum-sensing inhibitor (QSI) that attenuates QS-regulated virulence phenotypes in P. aeruginosa without affecting the growth of bacterias, serves as a leading compound for the treatment of P. aeruginosa infections .

HY-15592A

Cabotegravir sodium 5 Publications Verification GSK-1265744 sodium; S/GSK1265744 sodium	HIV HIV Integrase	Infection
Cabotegravir (GSK-1265744) sodium is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC₅₀ values of 2.5 nM, 0.41 μM and 0.81 μM for HIV_ADA, OAT3 and OAT1, respectively. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir sodium can be used to research AIDS .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0457A

L-Chicoric Acid 1 Publications Verification (-)-Chicoric acid; trans-Caffeoyltartaric acid	Structural Classification other families Classification of Application Fields Simple Phenylpropanols Source classification Phenols Polyphenols Phenylpropanoids Plants Disease Research Fields Cancer	HIV Integrase HIV Endogenous Metabolite
L-Chicoric Acid ((-)-Chicoric acid) is a dicaffeoyltartaric acid and a potent, selective and reversible HIV-1 integrase inhibitor with an IC₅₀ of ~100 nM. L-Chicoric Acid inhibits HIV-1 replication in tissue culture .

HY-N6711

Equisetin	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Disease Research Fields Other Antibiotics	HIV Integrase
Equisetin is an N-methylserine-derived acyl tetramic acid isolated from a terrestrial fungus Fusarium equiseti NRRL 5537 . Equisetin is a tetramate-containing natural product with antibiotic and cytotoxic activity . Equisetin inhibits the growth of Gram-positive bacteria and HIV-1 integrase activity but shows no activity against Gram-negative bacteria . Equisetin is a Quorum-sensing inhibitor (QSI) that attenuates QS-regulated virulence phenotypes in P. aeruginosa without affecting the growth of bacterias, serves as a leading compound for the treatment of P. aeruginosa infections .

HY-N7330

Integracin B	Infection Microorganisms Classification of Application Fields Source classification Phenols Polyphenols Disease Research Fields	HIV Integrase HIV
Integracin B is a potent dimeric alkyl aromatic inhibitor of HIV-1 integrase discovered from the screening of fungal extracts using an in vitro assay. Integracin B inhibits both coupled and strand transfer activity of HIV-1 integrase .

HY-N11288

Methyl salvionolate A	Structural Classification Labiatae Source classification Phenols Polyphenols Salvia yunnanensis C. H. Wright Plants	HIV
Methyl salvionolate A is a potent inhibitor of HIV-1. Methyl salvionolate A inhibits P24 antigen in HIV-1 infected MT-4 cell with an EC₅₀ of 1.62 μg/ml. Methyl salvionolate A also inhibits HIV-1 reverse transcriptase, protease and integrase with IC₅₀s of 50.58, 10.73 and 7.58 μg/ml, respectively .

Cat. No.	Product Name	Chemical Structure

HY-10353S

Raltegravir-d4

Raltegravir-d₄ is deuterium labeled Raltegravir. Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.

HY-10353AS

Raltegravir-d3 potassium
Raltegravir-d₃ (potassium) is the deuterium labeled Raltegravir potassium. Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection[1][2].

HY-W751039

Bictegravir-d4

Bictegravir-d4 is a deuterium of Bictegravir (HY-17605). Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC₅₀ of 7.5 nM .

HY-15592AS

Cabotegravir-d3 sodium
Cabotegravir-d₃ (sodium) is the deuterium labeled Cabotegravir sodium. Cabotegravir sodium is a highly potent HIV integrase inhibitor with an IC50 value of 2.5 nM for HIVADA. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltr

HY-15592S2

Cabotegravir-d3-1

Cabotegravir d3-1 (GSK-1265744-d3-1) is a deuterium substitute of Cabotegravir. Cabotegravir is a potent HIV integrase inhibitor used in AIDS research

HY-13238S1

Dolutegravir-d3

Dolutegravir-d₃ is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM)[1][2].

HY-13238S2

Dolutegravir-d5

Dolutegravir-d₅ is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM)[1][2].